KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) EBIT Margin: 2012-2025

Historic EBIT Margin for Sarepta Therapeutics (SRPT) over the last 11 years, with Jun 2025 value amounting to -49.16%.

  • Sarepta Therapeutics' EBIT Margin fell 4896.00% to -49.16% in Q2 2025 from the same period last year, while for Jun 2025 it was -6.34%, marking a year-over-year decrease of 886.00%. This contributed to the annual value of 11.47% for FY2024, which is 3301.00% up from last year.
  • As of Q2 2025, Sarepta Therapeutics' EBIT Margin stood at -49.16%, which was down 300.18% from 24.56% recorded in Q4 2024.
  • Sarepta Therapeutics' EBIT Margin's 5-year high stood at 24.56% during Q4 2024, with a 5-year trough of -103.36% in Q1 2021.
  • Moreover, its 3-year median value for EBIT Margin was -0.19% (2024), whereas its average is -13.03%.
  • Its EBIT Margin has fluctuated over the past 5 years, first skyrocketed by 7,704bps in 2021, then slumped by 4,896bps in 2025.
  • Sarepta Therapeutics' EBIT Margin (Quarterly) stood at -52.52% in 2021, then spiked by 1,118bps to -41.34% in 2022, then soared by 4,755bps to 6.21% in 2023, then spiked by 1,835bps to 24.56% in 2024, then plummeted by 4,896bps to -49.16% in 2025.
  • Its EBIT Margin was -49.16% in Q2 2025, compared to 24.56% in Q4 2024 and 4.75% in Q3 2024.